Literature DB >> 2884288

A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.

W M Watkins, J D Chulay, D G Sixsmith, H C Spencer, R E Howells.   

Abstract

Pharmacokinetic parameters for cycloguanil and chlorcycloguanil, the active metabolites of proguanil (Paludrine] and chlorproguanil (Lapudrine) have been measured in a bioassay which assesses the in-vitro growth inhibition of a cycloguanil- and chlorcycloguanil-sensitive strain of Plasmodium falciparum produced by dilutions of plasma collected after oral administration of the pro-drugs. A single compartment model is applicable for cycloguanil with mean rate constants of elimination of 0.0624 h-1 and availability of 0.2398 h-1. The elimination profile for chlorcycloguanil indicates partition of drug into more than one compartment. In 2 of 10 subjects dosed with proguanil and 1 of 11 subjects dosed with chlorproguanil, the active metabolite levels were significantly lower than the mean for the other subjects. Abnormally low cycloguanil or chlorcycloguanil plasma levels may be of importance in relation to effective prophylaxis against malaria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884288     DOI: 10.1111/j.2042-7158.1987.tb06263.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  24 in total

Review 1.  The evolution of drug-resistant malaria: the role of drug elimination half-life.

Authors:  Ian M Hastings; William M Watkins; Nicholas J White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

Review 2.  Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malaria.

Authors:  P A Winstanley; W M Watkins
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 3.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

4.  Warfarin potentiated by proguanil.

Authors: 
Journal:  BMJ       Date:  1991-09-28

5.  The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

Authors:  N A Helsby; S A Ward; G Edwards; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

6.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

7.  Development of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO Meetings.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

Review 8.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.

Authors:  E Holfels; J McAuley; D Mack; W K Milhous; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

Authors:  Julie A Simpson; Dyfrig Hughes; Christine Manyando; Kalifa Bojang; Leon Aarons; Peter Winstanley; Geoffrey Edwards; William A Watkins; Steve Ward
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.